Burkly Linda sold $13K of EDIT

Burkly Linda (EVP, CHIEF SCIENTIFIC OFFICER) sold 4,928 shares of Editas Medicine, Inc. (EDIT) at $2.67 on 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Burkly Linda
Published Jul 29, 2026, 8:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EDIT
Neutral
high confidence
Mentioned
$EDIT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EDITNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings by the EVP chief scientific officer under a 10b5-1 plan.

02

Market read

Traders may monitor insider activity, but this filing alone does not introduce new company fundamentals or catalysts.

03

What to watch

The transaction is explicitly under a pre-arranged 10b5-1 plan, which reduces the informational content versus discretionary selling.

Relevance 2/10Novelty 2/10Timing: Filed on 2026-07-29 after-hours, reflecting a 2026-07-28 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Editas Medicine, Inc.

Company-level read

Ticker impact

$EDITNeutralHigh confidence
Context

Editas Medicine disclosed an EVP chief scientific officer open-market sale of 4,928 shares at $2.67 on a 10b5-1 plan.

Expected impact

Likely minimal price impact; any reaction would be short-lived unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction, but it specifies a pre-arranged 10b5-1 plan and provides no new operational, financial, or regulatory information.

Market effects

No clear read-through to biotech sector fundamentals from a single routine 10b5-1 insider sale.

None.

None.

Counterpoint

Some traders may still view insider selling as a mild negative sentiment signal, especially if the stock is already under pressure, even when 10b5-1 is used.

Key entities

  • Editas Medicine, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Burkly Linda

    EVP, Chief Scientific Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EDITMed

Editas Medicine Reports Q3 2026 Results, $10.4M Revenue and $23.4M Net Loss

Editas Medicine reported Q3 2026 revenue of $10.4M and a net loss of $23.4M, improving from the same period last year. The company received Australian clearance for its Phase 1/2 Strive study of EDIT-401 and expects to dose the first patients this year. Editas anticipates its cash resources will fund operations into the second half of 2028. Preclinical data for EDIT-401 showed promising results in non-human primates.

$PRMEHighAI 8/10

StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance

Shares of gene editing therapy companies surged this week due to positive data from the ESGCT Congress and FDA draft guidance for personalized gene therapies. Prime Medicine (PRME) rose 29%, Beam Therapeutics (BEAM) 13%, Editas Medicine (EDIT) 11%, and Intellia Therapeutics (NTLA) 11%. The FDA's guidance aims to streamline approvals for individualized genome editing products. Analysts view the developments positively, anticipating continued momentum.

$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.